Navigation Links
Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
Date:12/27/2007

CYPRESS, Calif., Dec. 27 /PRNewswire/ -- A minimally invasive procedure called endometrial ablation is as effective as hysterectomy in solving a common female complaint called "dysfunctional uterine bleeding" or DUB, according to a new federally-funded study published in the Journal of Obstetrics and Gynecology.

DUB (dysfunctional uterine bleeding) can be described as abnormal bleeding which cannot be attributed to abnormalities of the female reproductive system, pharmacological interaction, intrauterine contraception, or bleeding disorders. It is also referred to menometrorrhagia.

The condition affects up to a third of all women at some point during their reproductive years, usually women over age 30. It is characterized by extremely heavy, erratic menstrual bleeding and is often accompanied by fatigue, pelvic pain and decreased quality of life. The excessive blood loss in DUB can provoke iron deficiency anemia.

"This is a very important study, proving that a minimally invasive procedure -- endometrial ablation -- can solve the problem of excessive bleeding as well as hysterectomy," commented Franklin D. Loffer, M.D., Executive Vice President/Medical Director of AAGL, the professional organization dedicated to the advancement of minimally-invasive gynecologic surgery. "Women should always be offered the least invasive, effective approach to solving her medical problems."

While hysterectomy (the removal of the uterus and in some cases the ovaries and cervix) has a long history of use to cure DUB, newer, less invasive procedures have become available in recent years. These have stirred controversy over whether hysterectomy is overused, particularly for conditions such as DUB for which more conservative approaches may be just as effective and cause fewer complications.

The new study, bearing the acronym of StopDUB for "Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding," was a multi-center, randomized, con
'/>"/>

SOURCE AAGL
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Corp ., a non-profit development company that helps small businesses, ... technology businesses. , ,MDC said it has closed on loans ... off of Lucigen Corp. , and to BioSystem ... Contest. , ,C5-6 Technologies, which will develop enzymes used to ...
... series of articles on developing start-up companies in the technology or ... entity. , , Madison, Wis. - Now ... to the type of entity to use, you should have concerned ... people think of first. Income taxes depend upon the type of ...
... - Jim Rice, who has served as president and CEO ... the past year, will leave ITAWi after an agreed-upon transition ... organization announced. , ,ITAWi's Board of Director has begun ... will assume Rice's duties until a replacement is found. Rice ...
Cached Biology Technology:Early Stage: Step 6 - Taxes, taxes, taxes! 2Early Stage: Step 6 - Taxes, taxes, taxes! 3Early Stage: Step 6 - Taxes, taxes, taxes! 4Rice to leave Wisconsin technology association 2
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Virology of the GSF National Research Center for ... Research Centres) the group is continuing to search for ... of a prion infection. In collaboration with colleagues from ... Heidelberg, the group used micro-array technologies micro-arrays ...
... plant cell biologist at UC Riverside has received a ... investigate how plant stem-cells maintain their identity and how ... According to G. Venugopala Reddy, the principal investigator of ... on plants, has potential to lead to better insights ...
... infant formula-- may reduce a babys susceptibility to rotavirus ... a University of Illinois study published in Septembers Journal ... diarrhea in infants, affecting virtually all children before age ... dehydration, doctors visits, and parents missing work to care ...
Cached Biology News:Prions and retroviruses -- an unholy alliance? 2UCR plant cell biologist to study how plant stem cells maintain and change their identity 2Soy isoflavone may inhibit common gastrointestinal illness in infants 2
Request Info...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Blimp-1 (H-150)...
Biology Products: